Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.17 Analyst target: $13.50 Upside: 8076.86%
Senti Biosciences Inc (SNTI) is a leading biotechnology firm specializing in synthetic biology, leveraging its proprietary GeneCircuit platform to create programmable cell and gene therapies. Focused on advancing personalized medicine, Senti targets critical challenges in oncology and genetic disorders, bolstered by a strong development pipeline and strategic collaborations. The company is poised for growth as it aims to revolutionize engineered cell therapy and address substantial unmet medical needs within the biopharmaceutical landscape, making it a compelling prospect for institutional investors.
See the full interactive analysis & chart →Informational only — not investment advice.